295 related articles for article (PubMed ID: 23987999)
1. Anti-apoptotic serpins as therapeutics in cardiovascular diseases.
Kuiper J; Quax PH; Bot I
Cardiovasc Hematol Disord Drug Targets; 2013 Aug; 13(2):111-22. PubMed ID: 23987999
[TBL] [Abstract][Full Text] [Related]
2. Viral serine protease inhibitors as anti-atherosclerotic therapy.
Bot I; van Berkel TJ; Biessen EA
Curr Opin Investig Drugs; 2007 Sep; 8(9):729-35. PubMed ID: 17729184
[TBL] [Abstract][Full Text] [Related]
3. The serpin solution; targeting thrombotic and thrombolytic serine proteases in inflammation.
Chen H; Davids JA; Zheng D; Bryant M; Bot I; van Berckel TJ; Biessen E; Pepine C; Ryman K; Progulski-Fox A; Kesavalu L; Moyer R; McFadden G; Lucas A
Cardiovasc Hematol Disord Drug Targets; 2013 Aug; 13(2):99-110. PubMed ID: 23987998
[TBL] [Abstract][Full Text] [Related]
4. Granzyme B as a novel factor involved in cardiovascular diseases.
Saito Y; Kondo H; Hojo Y
J Cardiol; 2011 Mar; 57(2):141-7. PubMed ID: 21168312
[TBL] [Abstract][Full Text] [Related]
5. Serpins, the vasculature, and viral therapeutics.
Richardson J; Viswanathan K; Lucas A
Front Biosci; 2006 Jan; 11():1042-56. PubMed ID: 16146796
[TBL] [Abstract][Full Text] [Related]
6. Serpins for diagnosis and therapy in cancer.
Zheng D; Chen H; Davids J; Bryant M; Lucas A
Cardiovasc Hematol Disord Drug Targets; 2013 Aug; 13(2):123-32. PubMed ID: 23988000
[TBL] [Abstract][Full Text] [Related]
7. Viral SERPINS-A Family of Highly Potent Immune-Modulating Therapeutic Proteins.
Varkoly K; Beladi R; Hamada M; McFadden G; Irving J; Lucas AR
Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759793
[TBL] [Abstract][Full Text] [Related]
8. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease.
Alkhalil M
Curr Drug Metab; 2019; 20(1):72-82. PubMed ID: 30112987
[TBL] [Abstract][Full Text] [Related]
9. The role of protease inhibition with emphasis on the effects of inflammation and vascular immune phenomena.
Bilfinger TV; Stefano GB
Curr Pharm Des; 2002; 8(7):505-9. PubMed ID: 11945155
[TBL] [Abstract][Full Text] [Related]
10. Serpins as therapeutics--a potential biologic source for unique protein-based therapeutics.
Lucas A
Cardiovasc Hematol Disord Drug Targets; 2013 Aug; 13(2):89. PubMed ID: 23987996
[No Abstract] [Full Text] [Related]
11. Pharmacology and pharmacokinetics of LEX 032, a bioengineered serpin: the first of a potential new class of drugs.
Sands H; Hook JB
Drug Metab Rev; 1997; 29(1-2):309-28. PubMed ID: 9187523
[No Abstract] [Full Text] [Related]
12. The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics.
Lucas A; Liu L; Dai E; Bot I; Viswanathan K; Munuswamy-Ramunujam G; Davids JA; Bartee MY; Richardson J; Christov A; Wang H; Macaulay C; Poznansky M; Zhong R; Miller L; Biessen E; Richardson M; Sullivan C; Moyer R; Hatton M; Lomas DA; McFadden G
Adv Exp Med Biol; 2009; 666():132-56. PubMed ID: 20054981
[TBL] [Abstract][Full Text] [Related]
13. Protease Inhibitors in Tick Saliva: The Role of Serpins and Cystatins in Tick-host-Pathogen Interaction.
Chmelař J; Kotál J; Langhansová H; Kotsyfakis M
Front Cell Infect Microbiol; 2017; 7():216. PubMed ID: 28611951
[TBL] [Abstract][Full Text] [Related]
14. Siropins, novel serine protease inhibitors from gut microbiota acting on human proteases involved in inflammatory bowel diseases.
Mkaouar H; Akermi N; Mariaule V; Boudebbouze S; Gaci N; Szukala F; Pons N; Marquez J; Gargouri A; Maguin E; Rhimi M
Microb Cell Fact; 2016 Nov; 15(1):201. PubMed ID: 27894344
[TBL] [Abstract][Full Text] [Related]
15. Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty.
Lucas A; Liu L; Macen J; Nash P; Dai E; Stewart M; Graham K; Etches W; Boshkov L; Nation PN; Humen D; Hobman ML; McFadden G
Circulation; 1996 Dec; 94(11):2890-900. PubMed ID: 8941118
[TBL] [Abstract][Full Text] [Related]
16. Viral-derived Serp-1 as an adjunctive therapy for percutaneous coronary intervention: another not ready for prime time player?
Leopold JA
Circ Cardiovasc Interv; 2010 Dec; 3(6):528-30. PubMed ID: 21156927
[No Abstract] [Full Text] [Related]
17. Serpins inhibit the toxicity of amyloid peptides.
Schubert D
Eur J Neurosci; 1997 Apr; 9(4):770-7. PubMed ID: 9153583
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Tardif JC; L'Allier PL; Grégoire J; Ibrahim R; McFadden G; Kostuk W; Knudtson M; Labinaz M; Waksman R; Pepine CJ; Macaulay C; Guertin MC; Lucas A
Circ Cardiovasc Interv; 2010 Dec; 3(6):543-8. PubMed ID: 21062996
[TBL] [Abstract][Full Text] [Related]
19. Viral anti-inflammatory reagents: the potential for treatment of arthritic and vasculitic disorders.
Munuswamy-Ramanujam G; Khan KA; Lucas AR
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):331-43. PubMed ID: 17214579
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
